Editas Medicine, Inc.
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
EDIT | US
Overview
Corporate Details
- ISIN(s):
- US28106W1036
- LEI:
- Country:
- United States of America
- Address:
- 11 HURLEY ST., 2141 CAMBRIDGE
- Website:
- https://www.editasmedicine.com/
Description
Editas Medicine, Inc. is a clinical-stage biotechnology company specializing in the development of transformative genomic medicines using CRISPR-based gene editing technology. The company's mission is to discover, develop, and commercialize durable therapies for a broad range of serious and rare diseases by precisely correcting the underlying genetic causes. Leveraging its proprietary CRISPR/Cas9 and CRISPR/Cas12a editing platforms, Editas Medicine focuses on creating treatments for conditions such as sickle cell disease and other inherited disorders. The company's pipeline includes both in vivo medicines, which edit genes inside the body, and ex vivo engineered cell medicines.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Editas Medicine, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Editas Medicine, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Editas Medicine, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
